Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 03 2019
Historique:
received: 19 06 2018
revised: 25 09 2018
accepted: 28 11 2018
pubmed: 6 12 2018
medline: 28 5 2020
entrez: 6 12 2018
Statut: ppublish

Résumé

In-depth characterization of recurrent glioblastoma (rGBM) might contribute to a better understanding of the mechanisms behind tumor progression and enable rGBM treatment with targeted drugs. Expression of MMR proteins was partially or completely lost in 25.9% rGBM samples. Specifically, 12 samples showed partial or total MSH6 expression reduction. Conversely, 96.4% of GBM samples at diagnosis expressed MMR markers. WES disclosed lack of variants in MMR genes in primary samples, whereas two MSH6-negative rGBM samples shared a c.3438+1G>A* splicing Multilevel profiling of MMR-deficient rGBM uncovered hypermutated genotype uncoupled from enriched expression of immune-related markers. Assessment of MHC class I expression and TMB should be included in protocols aiming to identify rGBM patients potentially eligible for treatment with drugs targeting immune-checkpoint inhibitors.

Identifiants

pubmed: 30514778
pii: 1078-0432.CCR-18-1892
doi: 10.1158/1078-0432.CCR-18-1892
doi:

Substances chimiques

Biomarkers, Tumor 0
Histocompatibility Antigens Class I 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1828-1837

Informations de copyright

©2018 American Association for Cancer Research.

Auteurs

Stefano Indraccolo (S)

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy. stefano.indraccolo@unipd.it.

Giuseppe Lombardi (G)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.

Matteo Fassan (M)

Department of Medicine (DIMED), Surgical Pathology Unit, University of Padova, Padova, Italy.

Lorenza Pasqualini (L)

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.

Silvia Giunco (S)

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.

Raffaella Marcato (R)

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.

Alessandra Gasparini (A)

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.

Cinzia Candiotto (C)

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.

Silvia Nalio (S)

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.

Pasquale Fiduccia (P)

Clinical Trials and Biostatistics Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.

Giuseppe Nicolò Fanelli (GN)

Department of Medicine (DIMED), Surgical Pathology Unit, University of Padova, Padova, Italy.

Ardi Pambuku (A)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.

Alessandro Della Puppa (A)

Neurosurgery Department, Azienda Ospedaliera di Padova, Padova, Italy.

Domenico D'Avella (D)

Neurosurgery, Department of Neurosciences DNS, University Hospital of Padova, Padova, Italy.

Laura Bonaldi (L)

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.

Marina Paola Gardiman (MP)

Surgical Pathology and Cytopathology Unit, University Hospital of Padova, Padova, Italy.

Roberta Bertorelle (R)

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.

Anita De Rossi (A)

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.
Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, Padova, Italy.

Vittorina Zagonel (V)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH